GLP-1 Medications in 2025: What Patients Need to Know Before Starting Semaglutide or Tirzepatide

The landscape of obesity and metabolic disease management has been fundamentally transformed by GLP-1 receptor agonists — and in 2025, these medications are more accessible, better studied, and more nuanced than ever before. Whether you've heard about Ozempic from a friend, seen Wegovy advertised online, or been referred to tirzepatide by your physician, understanding the full clinical picture before you start is essential. This guide, developed by Dr. Chomba Chuma, MD, Founder of iScript.care, is designed to give you the honest, physician-led information you deserve.

---

What Are GLP-1 Receptor Agonists — and Why Do They Matter?

GLP-1 stands for glucagon-like peptide-1, a naturally occurring hormone released by your gut in response to food. It plays several critical roles in metabolic regulation:

Stimulates insulin secretion in a glucose-dependent manner (reducing hypoglycemia risk)

Suppresses glucagon to lower blood sugar levels

Slows gastric emptying, which promotes satiety and reduces post-meal glucose spikes

Acts on the brain — particularly the hypothalamus — to reduce appetite and food cravings

GLP-1 receptor agonists are synthetic versions or analogs of this hormone, designed to stay active in the body far longer than the native peptide, which is degraded within minutes.

Originally developed for Type 2 diabetes management, these medications have rapidly evolved into frontline treatments for chronic weight management, cardiovascular risk reduction, and — with emerging evidence — conditions like metabolic-associated steatotic liver disease (MASLD) and even early Alzheimer's disease.

The Major Players in 2025

The GLP-1 medication landscape now includes several distinct agents. The two most prescribed for weight loss are:

Semaglutide — available as Ozempic (diabetes), Wegovy (obesity), and Rybelsus (oral, diabetes)

Tirzepatide — available as Mounjaro (diabetes) and Zepbound (obesity)

Tirzepatide is technically a dual agonist, activating both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors — a distinction that significantly affects its efficacy profile.

---

Semaglutide vs. Tirzepatide: A Clinical Comparison

Understanding the differences between these two drug classes is critical before selecting a treatment plan. Both are administered as once-weekly subcutaneous injections (with semaglutide also available orally), but they differ meaningfully in mechanism, efficacy, and tolerability.

Efficacy: The Weight Loss Data

The clinical trial data is striking:

STEP 1 trial (semaglutide 2.4mg/week): Average weight loss of ~15% of body weight over 68 weeks (NEJM, 2021)

SURMOUNT-1 trial (tirzepatide 15mg/week): Average weight loss of ~20.9% of body weight over 72 weeks

Participants on tirzepatide's highest dose achieved losses exceeding 25% in some subgroups

Clinical Insight: A head-to-head indirect comparison published in JAMA Internal Medicine found tirzepatide consistently outperformed semaglutide across all weight loss endpoints. However, individual response varies — and the "best" drug is the one a patient can tolerate, afford, and adhere to long term.

Cardiovascular Benefits

Beyond weight loss, these medications are now proven cardioprotective:

SELECT Trial (semaglutide): Reduced major adverse cardiovascular events (MACE) by 20% in overweight or obese patients with established cardiovascular disease but without diabetes

SURPASS-CVOT (tirzepatide): Results anticipated in 2025 are confirming strong cardiovascular signal

Side Effect Profiles

Both medications share a common side effect profile, primarily GI-related:

Nausea, vomiting, diarrhea, constipation

Decreased appetite (often desired but can become problematic)

Rare: pancreatitis, gallbladder disease, tachycardia

Tirzepatide may cause slightly more GI side effects at higher doses but some studies suggest better tolerability due to the GIP component's gastric-motility modulating effects.

---

Data Table: Semaglutide vs. Tirzepatide at a Glance

| Feature | Semaglutide (Wegovy/Ozempic) | Tirzepatide (Zepbound/Mounjaro) |

|---|---|---|

| Mechanism | GLP-1 agonist | Dual GLP-1 + GIP agonist |

| FDA Approved For | T2D, obesity, CVD risk reduction | T2D, obesity |

| Avg. Weight Loss (max dose) | ~15% body weight | ~20–21% body weight |

| Dosing Frequency | Once weekly (inj.) or daily (oral) | Once weekly (injection) |

| Starting Dose | 0.25 mg/week | 2.5 mg/week |

| Max Dose | 2.4 mg/week (Wegovy) | 15 mg/week (Zepbound) |

| Cardiovascular Indication | Yes (SELECT trial) | Pending (strong evidence) |

| Insurance Coverage (2025) | Variable; Wegovy expanding | Variable; Zepbound expanding |

| Compounded Availability | Yes (with FDA caveats) | Yes (with FDA caveats) |

| Cost Without Insurance | ~$900–$1,400/month | ~$1,000–$1,500/month |

---

Infographic Insight: Your GLP-1 Journey — Key Steps and Stats

The following data points should be illustrated as a patient journey infographic, moving from left to right with icons representing each milestone. A clean, clinical design with iScript.care branding is recommended.

🔬 Step 1 — Eligibility Assessment: GLP-1 therapy is FDA-approved for adults with a BMI ≥30, or ≥27 with at least one weight-related comorbidity (hypertension, T2D, dyslipidemia)

💉 Step 2 — Dose Titration (Weeks 1–16+): Both medications begin at low doses and are gradually increased over months to minimize GI side effects and find each patient's optimal dose

📉 Step 3 — Early Results (Months 1–3): Most patients lose 5–8% of body weight in the first 12 weeks; plateaus are normal and expected

🫀 Step 4 — Cardiometabolic Monitoring: Blood pressure, HbA1c, lipid panels, and kidney function should be monitored regularly — iScript.care's remote patient monitoring devices make this seamless

🧠 Step 5 — Behavioral Integration: GLP-1 medications work best alongside nutritional counseling and physical activity — medication is a tool, not a standalone cure

♾️ Step 6 — Long-Term Maintenance: Studies show weight regain occurs in most patients who discontinue therapy — ongoing treatment and monitoring is often medically appropriate

---

Who Is a Good Candidate for GLP-1 Therapy?

Not every patient is an ideal candidate, and responsible prescribing requires a thorough evaluation. As part of iScript.care's GLP-1 program, every patient undergoes a physician-reviewed assessment before any prescription is generated.

Ideal Candidates Include:

Adults with BMI ≥ 30 (obesity)

Adults with BMI ≥ 27 plus at least one weight-related comorbidity

Patients with Type 2 diabetes who need better glycemic control

Patients with established cardiovascular disease and overweight/obesity (per SELECT trial data)

Individuals who have struggled with weight loss through diet and exercise alone

Who Should Avoid GLP-1 Medications:

Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) — both are absolute contraindications

History of pancreatitis (use with caution)

Pregnancy or breastfeeding (must be discontinued at least 2 months before conception for semaglutide)

Patients with severe gastroparesis or other GI motility disorders

Patients with active eating disorders (requires specialized psychiatric co-management)

Special Considerations in 2025

One of the most important clinical debates in 2025 centers on muscle mass preservation. GLP-1 medications cause fat loss but can also result in significant lean muscle loss — sometimes accounting for 25–40% of total weight lost. This is why resistance training and adequate protein intake (1.2–1.6g per kg body weight) are not optional recommendations — they are medically important.

At iScript.care, our telehealth programs incorporate behavioral health and nutritional guidance as part of a complete care model, not an afterthought.

---

The Compounded Semaglutide Question: What Patients Must Know in 2025

During the 2022–2024 shortage period, compounded versions of semaglutide and tirzepatide became widely available through online pharmacies and telehealth platforms. In 2025, the landscape has shifted:

The FDA declared the semaglutide shortage resolved in early 2024, making large-scale compounding no longer automatically permissible

503A and 503B pharmacies may still compound these medications under specific clinical justifications, but patients should be aware of quality and regulatory considerations

The FDA has issued warnings about compounded semaglutide products that include unapproved salt forms (e.g., semaglutide sodium, acetate) — FDA safety communication

Brand-name medications with manufacturer coupons or savings programs may be more cost-effective and safer for many patients than compounded alternatives

Dr. Chomba Chuma's Clinical Perspective: "The question I get most from patients is whether compounded semaglutide is 'just as good.' The honest answer is: we don't know, because it hasn't been through the same rigorous testing. At iScript.care, we always prioritize FDA-approved medications when accessible, and work hard to help patients navigate insurance and savings programs to make that happen."

---

Navigating Insurance, Coverage, and Access in 2025

Cost and access remain the most significant barriers to GLP-1 therapy for many patients. Here's what the landscape looks like:

Insurance Coverage

Medicare: As of 2025, Wegovy is covered under Medicare Part D for patients with established cardiovascular disease following the expanded SELECT trial indication — a landmark policy shift

Medicaid: Coverage varies widely by state; many states now cover at least one GLP-1 medication for diabetes

Commercial Insurance: Coverage is improving but inconsistent; prior authorizations are common and often require documentation of failed lifestyle interventions

Manufacturer Savings Programs

Novo Nordisk (Ozempic/Wegovy): Offers savings cards reducing cost to as low as $0/month for eligible commercially insured patients

Eli Lilly (Mounjaro/Zepbound): Similar savings programs; Zepbound has an innovative self-pay vial program at significantly reduced cost

The Role of Telehealth in Access

According to the CDC, more than 40% of U.S. adults have obesity — yet fewer than 3% of eligible patients ever receive pharmacological treatment. The access gap is enormous, and telehealth is a powerful solution.

Through iScript.care's physician network, patients can access GLP-1 prescriptions through a streamlined, HIPAA-compliant telehealth visit — eliminating geographic and logistical barriers that prevent millions from receiving evidence-based care.

---

How iScript.care Approaches GLP-1 Care Differently

Founded by Dr. Chomba Chuma, MD, iScript.care was built on the principle that technology should amplify physician expertise — not replace it. Our approach to GLP-1 management reflects this philosophy at every step.

What Sets Our GLP-1 Program Apart:

Doctor-Led, Every Time: Every GLP-1 prescription on iScript.care is reviewed and authorized by a licensed physician — not a nurse practitioner working from an algorithm alone

AI-Powered Clinical Intelligence: Our platform uses intelligent clinical decision support to flag contraindications, drug interactions, and monitoring gaps before they become problems

Integrated Remote Monitoring: Through our chronic care and RPM program, patients on GLP-1 therapy can have their blood pressure, glucose, and weight tracked continuously — with clinical alerts sent directly to their care team

Ongoing Clinical Check-ins: GLP-1 therapy is not "prescribe and forget." Our platform builds in structured follow-up visits and labs review at 4, 12, and 24 weeks

Full Transparency: Visit our FAQ page to understand exactly what's included in your care plan before you commit

---

Common Questions Patients Ask Before Starting

"How long until I see results?"

Most patients notice reduced appetite within the first 1–2 weeks. Measurable weight loss (3–5% of body weight) typically occurs by week 4–8. Maximum efficacy is usually reached at 6–12 months on a therapeutic dose.

"Will I need to be on this medication forever?"

This is one of the most important conversations to have with your physician. Current evidence suggests GLP-1 medications work while you take them — most patients regain a significant portion of weight within 1–2 years of stopping. This does not mean failure; it means obesity is a chronic disease requiring chronic management, similar to how we approach hypertension or diabetes.

"Can I take GLP-1 medications with other drugs?"

Important interactions exist, particularly with:

Oral medications (slower gastric emptying can alter absorption timing)

Insulin and sulfonylureas (hypoglycemia risk requires dose adjustment)

Warfarin (INR monitoring may be needed)

Always disclose your full medication list during your clinical assessment. Our platform's clinical review process is specifically designed to catch these interactions.

---

Conclusion

GLP-1 receptor agonists represent one of the most significant advances in metabolic medicine in decades. Whether you're considering semaglutide (Ozempic or Wegovy) or tirzepatide (Mounjaro or Zepbound), making an informed, physician-guided decision is the foundation of safe and effective treatment.

In 2025, the data is compelling: these medications can produce 15–21% body weight reduction, meaningfully reduce cardiovascular risk, improve glycemic control, and address a wide spectrum of metabolic conditions. But they are not magic. They require proper evaluation, ongoing monitoring, dose management, and integration with lifestyle strategies to deliver their full potential.

At iScript.care, every patient who walks through our virtual doors receives the same commitment: a rigorous, physician-led clinical assessment, an AI-powered care platform that doesn't let anything fall through the cracks, and ongoing monitoring through industry-leading remote patient monitoring tools. This is the standard Dr. Chomba Chuma, MD built iScript.care to deliver — and the standard every GLP-1 patient deserves.

Explore our blog library for more in-depth guides on GLP-1 medications, chronic care management, and the future of telehealth.

---

Ready to find out if GLP-1 therapy is right for you? The first step is a comprehensive, physician-reviewed assessment — and it starts right here. Contact iScript.care today or begin your free telehealth assessment to speak with a licensed provider, review your eligibility, and take the first step toward evidence-based, personalized metabolic care.

This article is intended for educational purposes and does not constitute individualized medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.